ZDA
ISEE

Zweig-DiMenna Associates’s IVERIC bio, Inc. Common Stock ISEE Stock Holding History

Zweig-DiMenna Associates’s Portfolio ISEE Stock Details ISEE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q3 		– Sell
-25,000
Closed -$1.06M – 328
2014
Q2 		$1.06M Hold
25,000
– – 0.05% 134
2014
Q1 		$892K Buy
+25,000
New +$843K 0.05% 121

Other funds holding ISEE

NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SHI
SV Health Investors Boston, Massachusetts $32.3M AUM 20.15% 1-Year Est. Return
JCG
JHL Capital Group Chicago, Illinois $805M AUM 50.84% 1-Year Est. Return
CV
Clarus Ventures Cambridge, Massachusetts $425M AUM 26.13% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Zweig-DiMenna Associates's ISEE Position: Q3 2014 in Review

Zweig-DiMenna Associates sold out of IVERIC bio, Inc. Common Stock (ISEE) in Q3 2014, closing a stake of 25,000 shares — an estimated $1.06M sold.

Zweig-DiMenna Associates first reported a position in ISEE in Q1 2014 and held it in 2 quarters. The position peaked at $1.06M in Q2 2014. 92 funds tracked by Wall St. Rank hold ISEE as of Q3 2014.

  • Zweig-DiMenna Associates reported no remaining IVERIC bio, Inc. Common Stock position as of Q3 2014 after selling out during the quarter.
  • Zweig-DiMenna Associates sold 25,000 IVERIC bio, Inc. Common Stock shares in Q3 2014, an estimated $1.06M.
  • Zweig-DiMenna Associates first reported a position in IVERIC bio, Inc. Common Stock in Q1 2014 and held it in 2 quarters.
  • Zweig-DiMenna Associates's IVERIC bio, Inc. Common Stock position peaked at $1.06M in Q2 2014.
  • 92 funds tracked by Wall St. Rank held IVERIC bio, Inc. Common Stock as of Q3 2014.

Based on Zweig-DiMenna Associates's 13F filing for Q3 2014, filed 10 Nov 2014.